US buys Lilly COVID antibody, as effectiveness questions remainThe US government said it will buy 300,000 doses of Eli Lilly’s COVID-19 therapy bamlanivimab for $375 million Share XUS buys Lilly COVID antibody, as effectiveness questions remainhttps://pharmaphorum.com/news/us-buys-300000-doses-lilly-covid-antibody/
Exact Sciences buys cancer detection company Thrive for $2.15 billionStocks for Exact Sciences leaped 33% after it announced the acquisition of liquid biopsy rival Thrive and UK Share XExact Sciences buys cancer detection company Thrive for $2.15 billionhttps://pharmaphorum.com/news/exact-sciences-buys-early-cancer-detection-company-thrive-for-2-15-billion/
COVID-19 bites into Pfizer’s Q3, but biopharma revenues risePfizer is one of the front-runners in the race to approve a COVID-19 vaccine but the US company Share XCOVID-19 bites into Pfizer’s Q3, but biopharma revenues risehttps://pharmaphorum.com/news/covid-bites-into-pfizers-q3-but-biopharma-revenues-rise/
Catabasis craters after giving up on muscular dystrophy leadCatabasis has conceded defeat with its Duchenne muscular dystrophy drug edasalonexent, pulling the plug on the drug after Share XCatabasis craters after giving up on muscular dystrophy leadhttps://pharmaphorum.com/news/catabasis-craters-after-giving-up-on-muscular-dystrophy-lead/
NIAID drops Lilly antibody from ACTIV-3 COVID-19 trialEli Lilly says no more patients will be treated with its COVID-19 therapy bamlanivimab in a trial run Share XNIAID drops Lilly antibody from ACTIV-3 COVID-19 trialhttps://pharmaphorum.com/news/niaid-drops-lilly-antibody-from-activ-3-covid-19-trial/
BioSig abandons COVID-19 drug trial on safety concernsUS biotech BioSig Technologies has abandoned a phase 2 trial of its antiviral drug merimepodib with Gilead’s Veklury Share XBioSig abandons COVID-19 drug trial on safety concernshttps://pharmaphorum.com/news/biosig-abandons-covid-19-drug-trial-on-safety-concerns/
Bayer buys cell & gene therapy firm AskBio for $4 billionBayer is making clear its ambitions in cell and gene therapy with a $4 billion acquisition of US Share XBayer buys cell & gene therapy firm AskBio for $4 billionhttps://pharmaphorum.com/news/bayer-extends-reach-in-cell-gene-therapy-with-askbio-acquisition/
Bayer data for kidney disease hope finerenone sets up filingsBayer’s blockbuster ambitions for diabetic kidney disease (DKD) drug candidate finerenone look a lot firmer with the publication Share XBayer data for kidney disease hope finerenone sets up filingshttps://pharmaphorum.com/news/bayer-data-for-kidney-disease-hope-finerenone-sets-up-filings/
Moderna nears COVID-19 vaccine finish line as it wraps up study enrolmentModerna is close to completing its phase 3 trial of COVID-19 vaccine candidate mRNA-1273 after completing recruitment of Share XModerna nears COVID-19 vaccine finish line as it wraps up study enrolmenthttps://pharmaphorum.com/news/moderna-nears-covid-19-vaccine-finish-line-as-it-wraps-up-study-enrolment/
Convalescent plasma misses the mark in phase 2 trialHopes that antibody-laden plasma taken from recovered COVID-19 patients could lessen the severity of the disease in others Share XConvalescent plasma misses the mark in phase 2 trialhttps://pharmaphorum.com/news/convalescent-plasma-misses-the-mark-in-phase-2-trial/
Sarepta helps bankroll new gene therapy startup AavantiBioSarepta chief commercial officer Bo Cumbo has left to head up gene therapy venture – AavantiBio – with Share XSarepta helps bankroll new gene therapy startup AavantiBiohttps://pharmaphorum.com/news/sarepta-helps-bankroll-new-gene-therapy-startup-aavantibio/
Roche to co-develop remdesivir rival in partnership with AteaRoche may not be the first company that comes to mind for a COVID-19 treatment, but the Swiss Share XRoche to co-develop remdesivir rival in partnership with Ateahttps://pharmaphorum.com/news/roche-to-co-develop-remdesivir-rival-in-partnership-with-atea/
SparingVision raises €44.5m for retinitis pigmentosa gene therapyFrench biotech SparingVision has raised 44.5 million euros ($52.7 million) to develop its gene therapy for a rare Share XSparingVision raises €44.5m for retinitis pigmentosa gene therapyhttps://pharmaphorum.com/news/sparingvision-raises-44-5-million-euros-for-retinitis-pigmentosa-gene-therapy/
Adult data back Merck & Co’s challenger to Pfizer’s blockbuster Prevnar 13Merck & Co has built more momentum behind its attempt to depose Pfizer’s blockbuster pneumococcal conjugate vaccine Prevnar Share XAdult data back Merck & Co’s challenger to Pfizer’s blockbuster Prevnar 13https://pharmaphorum.com/news/adult-data-back-mercks-challenger-to-pfizers-blockbuster-prevnar-13/
AZ’s COVID-19 vaccine trial ready to resume in US – reportsAstraZeneca’s COVID-19 vaccine trial could be ready to resume this week in the US after a seven-week hiatus Share XAZ’s COVID-19 vaccine trial ready to resume in US – reportshttps://pharmaphorum.com/news/azs-covid-19-vaccine-trial-ready-to-resume-reports/
Trump launches tirade against NIAID chief Fauci as COVID-19 crisis escalatesThe war of words between Donald Trump and his top infectious diseases expert Dr Anthony Fauci has intensified Share XTrump launches tirade against NIAID chief Fauci as COVID-19 crisis escalateshttps://pharmaphorum.com/news/trump-launches-tirade-against-niaid-chief-fauci-as-covid-19-crisis-escalates/
UK government signs contract for COVID-19 challenge trialThe UK government has signed a contract to develop a controversial COVID-19 human challenge trial, where participants will Share XUK government signs contract for COVID-19 challenge trialhttps://pharmaphorum.com/news/uk-government-signs-contract-for-covid-19-challenge-trial/
Pfizer to wait until after election to file COVID-19 vaccine in USPfizer said it will wait until after the US election to file its COVID-19 vaccine with the US Share XPfizer to wait until after election to file COVID-19 vaccine in UShttps://pharmaphorum.com/news/pfizer-to-wait-until-after-election-to-file-covid-19-vaccine-in-us/
